Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

PegBio Receives $7.8M Milestone Payment from Tenry Pharma for Paidakang GLP-1 Agonist – Chinese Biotech Secures First Commercial Revenue from Type 2 Diabetes Asset

Fineline Cube Jun 8, 2026
Company Deals

Junshi Biosciences Forms Strategic JV with Zhiyu Biomedicine, Contributing Oncology Antibody IP and ADC Platform for Multispecific Development

Fineline Cube Jun 8, 2026
Company Deals

Everest Medicines Licenses LNZ100 Presbyopia Treatment from Corxel for Greater China – Aceclidine-Based Eye Drop Offers Novel Miotic Mechanism

Fineline Cube Jun 8, 2026
Company Deals

SSY Group Secures Global Rights to Pediatric Antispasmodic and COPD Drugs from Xinzheng Heying – Full IP Transfer in Category 2.2 and 2.3 Assets

Fineline Cube Jun 5, 2026
Company Deals

Lonza and Stipple Bio Forge Strategic ADC Partnership – Combining Epitope Discovery with Glyco Connect Platform for Next-Generation Oncology Therapies

Fineline Cube Jun 5, 2026
Policy / Regulatory

China’s NHC Releases Sixth Pediatric Drug Priority List – 27 Varieties Including Emicizumab, Pembrolizumab, and Omalizumab Targeted for Development

Fineline Cube Jun 5, 2026
Company Drug

Henlius Biotech Doses First US Patient in Global Phase I Trial of HLX17 Pembrolizumab Biosimilar – Dual FDA/NMPA Approval Enables Simultaneous Development in China and United States

Fineline Cube Jun 8, 2026
Company Drug

Novo Nordisk’s CagriSema Fixed-Dose Combination Delivers Superior HbA1c and Weight Loss in Phase 3 REIMAGINE Trials – Amylin/GLP-1 Dual Therapy Outperforms Semaglutide Monotherapy

Fineline Cube Jun 8, 2026
Company Drug

Jiangsu Hengrui Pharmaceuticals’ Tegileridine Approved for Postoperative Pain Management

Fineline Cube Mar 17, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced receiving another indication approval from the...

Company Drug

Doma Biopharmaceutical’s HER3-MUC1 Targeted ADC DM002 Receives NMPA Clinical Approval

Fineline Cube Mar 17, 2025

China-based Doma Biopharmaceutical (Suzhou) Co., Ltd announced receiving clinical approval from the National Medical Products...

Company Medical Device

MicroPort Endovascular MedTech’s Cratos System Approved for Aortic Dissection Treatment

Fineline Cube Mar 17, 2025

Shanghai MicroPort Endovascular MedTech Co., Ltd’s (SHA: 688016) Cratos branched aortic stent graft system has...

Company Drug

Akeso Biopharma’s Penpulimab Approved for First-Line NPC Treatment

Fineline Cube Mar 17, 2025

China-based Akeso Biopharma (HKG: 9926) announced receiving another indication approval from the National Medical Products...

Company Drug

Innovent Biologics’ Sycume Approved by China’s NMPA for Thyroid Eye Disease

Fineline Cube Mar 17, 2025

China-based Innovent Biologics Inc. (HKG: 1801) announced that its New Drug Application (NDA) for Sycume...

Company Drug

Simcere Pharmaceutical’s ADC189 NDA Accepted for Influenza Treatment

Fineline Cube Mar 17, 2025

Simcere Pharmaceutical Group Limited (HKG: 2096) and AnDiConBio announced that the New Drug Application (NDA)...

Company

Rona Therapeutics Secures $25M Pre-B Round to Advance siRNA Therapies

Fineline Cube Mar 16, 2025

Shanghai-based Rona Therapeutics announced the successful completion of a $25 million (RMB 180 million) Pre-B...

Company

Tonghua Golden-Horse Pharmaceutical Embraces AI with DeepSeek R1 for Drug Innovation

Fineline Cube Mar 16, 2025

Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd. (SHE: 000766) recently held a special meeting to deploy...

Digital

DeepSeek’s Rise in the Pharmaceutical Industry: A New Era of AI-Driven Transformation

Fineline Cube Mar 15, 2025

The emergence of DeepSeek-R1 during the Lunar New Year celebrations marked a pivotal moment in...

Company Deals

Pharmavan and Kefeng Changjian Sign Pact to Accelerate SPT-07A Development

Fineline Cube Mar 15, 2025

Suzhou Pharmavan Co., Ltd. has announced plans to enter into a cooperation agreement with Sichuan...

Company Drug

Roche’s Itovebi Approved in China for PIK3CA-Mutated Breast Cancer

Fineline Cube Mar 14, 2025

Itovebi (inavolisib), a best-in-class PI3Kα inhibitor from Swiss giant Roche (SWX: ROG, OTCMKTS: RHHBY), has...

Company Deals

Quantum Hi-Tech and ECNU Establish AI-Driven Drug Manufacturing Lab

Fineline Cube Mar 14, 2025

CRO+CDMO Quantum Hi-Tech (China) Biotechnology Co., Ltd (ChemPartner, SHE: 300149) announced plans to establish an...

Company Deals

BioCity and MSD Enter Clinical Collaboration for BC3195 and Keytruda Combination Trial

Fineline Cube Mar 14, 2025

China-based BioCity Biopharmaceutics Co., Ltd. announced a clinical collaboration agreement with US-based giant Merck, Sharp...

Company Deals Hospital

Shanghai Fosun Pharmaceutical Transfers Unicorn II Holdings Stake to Warburg Pincus Subsidiary

Fineline Cube Mar 14, 2025

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced plans to transfer...

Company Deals

Salipro Biotech and Boehringer Ingelheim Collaborate on Drug Development for Membrane Proteins

Fineline Cube Mar 14, 2025

Sweden-based Salipro Biotech AB announced a research and license agreement with German pharmaceutical giant Boehringer...

Company Drug

CSPC Pharmaceutical Group Receives FDA Approval for SYH2051 Clinical Trial

Fineline Cube Mar 14, 2025

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced receiving approval from the US Food and...

Company Medical Device

Gaush Meditech’s ANTERION Ophthalmic Detector Receives NMPA Market Approval

Fineline Cube Mar 14, 2025

Suzhou-based Gaush Meditech Ltd (HKG: 2407) announced receiving market approval from the National Medical Products...

Company Drug

Bio-Thera Solutions’ BAT2506 Biosimilar Accepted for Review by China’s NMPA

Fineline Cube Mar 14, 2025

China-based Bio-Thera Solutions Inc. (SHA: 688177) announced that a market filing for its BAT2506, a...

Company Drug

Otsuka and Lundbeck Win EU Approval for Rxulti in Adolescent Schizophrenia

Fineline Cube Mar 14, 2025

Japan-based Otsuka Pharmaceutical Co., Ltd and its Danish partner Lundbeck A/S (OTCMKTS: HLUBF) jointly announced...

Company Drug

Shanghai Fosun Pharmaceutical Gains NMPA Approval for XH-S003 in PNH Treatment

Fineline Cube Mar 14, 2025

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced receiving clinical trial...

Posts pagination

1 … 209 210 211 … 679

Recent updates

  • PegBio Receives $7.8M Milestone Payment from Tenry Pharma for Paidakang GLP-1 Agonist – Chinese Biotech Secures First Commercial Revenue from Type 2 Diabetes Asset
  • Sino Medical Sciences Secures Colombian Approval for HT Supreme Drug-Eluting Stent – Advanced Dual-Polymer Technology Expands Latin American Presence
  • Henlius Biotech Doses First US Patient in Global Phase I Trial of HLX17 Pembrolizumab Biosimilar – Dual FDA/NMPA Approval Enables Simultaneous Development in China and United States
  • Novo Nordisk’s CagriSema Fixed-Dose Combination Delivers Superior HbA1c and Weight Loss in Phase 3 REIMAGINE Trials – Amylin/GLP-1 Dual Therapy Outperforms Semaglutide Monotherapy
  • Bayer’s Kerendia (Finerenone) Demonstrates Significant Kidney Protection in Non-Diabetic CKD Phase III Trial – First Mineralocorticoid Receptor Antagonist to Show Efficacy Beyond Diabetes Population
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

PegBio Receives $7.8M Milestone Payment from Tenry Pharma for Paidakang GLP-1 Agonist – Chinese Biotech Secures First Commercial Revenue from Type 2 Diabetes Asset

Company Medical Device

Sino Medical Sciences Secures Colombian Approval for HT Supreme Drug-Eluting Stent – Advanced Dual-Polymer Technology Expands Latin American Presence

Company Drug

Henlius Biotech Doses First US Patient in Global Phase I Trial of HLX17 Pembrolizumab Biosimilar – Dual FDA/NMPA Approval Enables Simultaneous Development in China and United States

Company Drug

Novo Nordisk’s CagriSema Fixed-Dose Combination Delivers Superior HbA1c and Weight Loss in Phase 3 REIMAGINE Trials – Amylin/GLP-1 Dual Therapy Outperforms Semaglutide Monotherapy

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.